Haha, perhaps. But that's the kind of confidence I want to see with Dr. Missling. I still think it's a coin toss whether the FDA approves Blarcamesine, with or without another P3 or P4 trial. Rett will be the canary in the coal mine but I just don't know what the company will do with all that cash but I hate that it'll be sitting there.
Again, if 273 doesn't pan out they can invest $500 million in A371 and most investors won't want to touch the stock with a 10 foot pole because confidence in Sigma-1 will have been drastically eroded.